Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus‐Cruces‐Bordeaux Inception Cohort
Arthritis Care & Research · 2024
DOI: 10.1002/acr.25334 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Guillermo Ruiz-Irastorza und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biobizkaia Health Research Institute and University of The Basque Country-UPV/EHU, Bizkaia, Basque Country, Spain. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Methylprednisolone, Remission Induction, Propensity Score. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hezkuntza Saila, Eusko Jaurlaritza, Consejería de Transformación Económica, Industria, Conocimiento y Universidades, Junta de Andalucía-Sevilla, Hezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza.
Abstract (Originalsprache)
Objective
The objective of this study was to analyze the effect of methylprednisolone pulses (MP), given during the first year after the diagnosis of systemic lupus erythematosus (SLE), in achieving prolonged remission according to the degree of lupus activity at presentation.
Methods
We conducted an observational study of routine clinical care data from the Lupus‐Cruces‐Bordeaux cohort. The end point was prolonged remission (ie, during five consecutive yearly visits). The effect of MP on remission during the first year was analyzed in the whole cohort and according to the baseline Systemic Lupus Erythematosus Disease Activity Index 2000 score: 12, reflecting mild, moderate, and severe activity, respectively. For adjustment, logistic regression with propensity score (PS) and other therapeutic covariates was performed.
Results
Two hundred thirty‐three patients were included. Prolonged remission was achieved by 132 patients (57%). MP were associated with prolonged remission (PS‐adjusted odds ratio [OR] 2.50, 95% confidence interval [CI] 1.04–623, P = 0.042). A strong clinical effect was seen among patients with moderate (adjusted OR 5.28, 95% CI 1.27–21.97, P = 0.022) and moderate‐severe SLE activity (adjusted OR 4.07, 95% CI 1.11–14.82, P = 0.033). The administration of MP resulted in reduced average dosages of prednisone during the first year among patient with moderate (mean 6.6 vs 10.2 mg/day, P = 0.017) and severe activity (mean 14 vs 28 mg/day, P = 0.015). The odds of prolonged remission were increased by longer‐term use of hydroxychloroquine (HCQ) and decreased by higher initial doses of prednisone.
Conclusion
This study supports the use of MP to induce prolonged remission in patients with SLE, particularly in those with moderate and severe activity. The extended use of HCQ also contributes to achieve prolonged remission. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Biobizkaia Health Research Institute and University of The Basque Country-UPV/EHU, Bizkaia, Basque Country, Spain.
- Biobizkaia Health Research Institute, Bizkaia, Basque Country, Spain.
- University of The Basque Country-UPV/EHU, Bizkaia, Basque Country, Spain.
- Hospital Universitario Cruces, Bizkaia, Basque Country, UNIR Health Sciences School and Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
- Hospital Universitario Cruces, Bizkaia, Basque Country, Hospital Regional Universitario de Málaga and Universidad de Málaga, Málaga, Spain.
- Bordeaux Hospital University, Bordeaux, France.
ORCID-Profile: Guillermo Ruiz-Irastorza, Diana Paredes-Ruiz, Victor Moreno-Torres, Halbert Hernandez-Negrin, Ioana Ruiz-Arruza, Christophe Richez, Estibaliz Lazaro
Förderung
- Hezkuntza Saila, Eusko Jaurlaritza
- Consejería de Transformación Económica, Industria, Conocimiento y Universidades, Junta de Andalucía-Sevilla
- Hezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza
- Consejería de Transformación Económica, Industria, Conocimiento y Universidades
Zitieren
APA
Ruiz-Irastorza, G., Paredes-Ruiz, D., Herrero-Galvan, M., Moreno-Torres, V., Hernandez-Negrin, H., Ruiz-Arruza, I., Leonard, C., Richez, C., & Lazaro, E. (2024). Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus‐Cruces‐Bordeaux Inception Cohort. Arthritis Care & Research. https://doi.org/10.1002/acr.25334
Vancouver
Ruiz-Irastorza G, Paredes-Ruiz D, Herrero-Galvan M, Moreno-Torres V, Hernandez-Negrin H, Ruiz-Arruza I, et al. Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus‐Cruces‐Bordeaux Inception Cohort. Arthritis Care & Research. 2024. doi:10.1002/acr.25334
BibTeX
@article{RuizIrastorza2024,
author = {Ruiz-Irastorza, Guillermo and Paredes-Ruiz, Diana and Herrero-Galvan, Maria and Moreno-Torres, Victor and Hernandez-Negrin, Halbert and Ruiz-Arruza, Ioana and Leonard, Cedric and Richez, Christophe and Lazaro, Estibaliz},
title = {Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus‐Cruces‐Bordeaux Inception Cohort},
journal = {Arthritis Care & Research},
year = {2024},
doi = {10.1002/acr.25334}
}
EUVIMED